Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target lifted by stock analysts at JPMorgan Chase & Co. from ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Citigroup said it’s “very bullish” on Gilead’s HIV franchise, arguing it’s the drugmaker’s biggest value driver as the company’s new ...

The latest analyst rating for Gilead Sciences (NASDAQ:GILD) was provided by Morgan Stanley, and Gilead Sciences maintained their overweight rating. The last upgrade for Gilead Sciences Inc ...

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare and Life Sciences — and remains the firm’s largest owner, though more than 20 of ...

Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Investor model based on the published ...

To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future". Over the twelve months to December 2024, Gilead Sciences recorded an accrual ...

FOSTER CITY, Calif., March 12, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...